Luxena Pharmaceuticals

Luxena Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of various cancers. The company's lead candidate, LX-101, is a potent and selective inhibitor of PIM kinases (PIM-1, PIM-2, and PIM-3), which are known to play a critical role in cell survival and proliferation in hematologic malignancies and solid tumors. Luxena is currently evaluating LX-101 in Phase 1/2 clinical trials for patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell malignancies. The company aims to address unmet medical needs by targeting pathways that drive resistance to current standard-of-care therapies.